Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News New typhoid vaccine ‘represents potential breakthrough’

New typhoid vaccine ‘represents potential breakthrough’

3rd October 2017

Researchers have demonstrated the potentially significant benefits offered by a promising new vaccine for typhoid.

An Oxford University team evaluated the Vi-tetanus toxoid conjugate vaccine among around 100 study participants, showing that it was both safe and effective in preventing the disease.

Typhoid is associated with inadequate sanitation and contaminated drinking water, with common symptoms including fever, stomach pain, headache and constipation or diarrhoea.
Although children are especially susceptible, current vaccines do not confer lasting immunity in children, or come in inappropriate formats.

By contrast, the new typhoid conjugate vaccine was shown to be safe, well tolerated and to offer the potential for a significant impact on disease incidence in typhoid-endemic areas that introduce it.

Professor Andrew Pollard, director of the Oxford Vaccine Group, said: "This new vaccine could be a real gamechanger in tackling a disease that disproportionately affects both poor people and children."

Typhoid is responsible for around 20 million new infections and 200,000 deaths each year, mainly in Africa and south and south-east Asia.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.